Cadinha & Co. LLC Sells 1,070 Shares of Danaher Co. (NYSE:DHR)

Cadinha & Co. LLC lowered its stake in shares of Danaher Co. (NYSE:DHR) by 15.7% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 5,763 shares of the conglomerate’s stock after selling 1,070 shares during the quarter. Cadinha & Co. LLC’s holdings in Danaher were worth $1,602,000 at the end of the most recent quarter.

A number of other institutional investors have also recently made changes to their positions in DHR. Tsfg LLC increased its holdings in shares of Danaher by 733.3% in the 1st quarter. Tsfg LLC now owns 100 shares of the conglomerate’s stock worth $25,000 after purchasing an additional 88 shares in the last quarter. nVerses Capital LLC purchased a new stake in Danaher during the second quarter worth $25,000. CarsonAllaria Wealth Management Ltd. purchased a new stake in Danaher in the second quarter valued at about $25,000. Redmont Wealth Advisors LLC purchased a new position in shares of Danaher in the first quarter worth about $30,000. Finally, Richardson Financial Services Inc. purchased a new position in Danaher during the fourth quarter valued at approximately $42,000. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Danaher Trading Down 0.7 %

DHR traded down $1.83 during midday trading on Thursday, reaching $267.40. 98,275 shares of the company were exchanged, compared to its average volume of 2,724,729. Danaher Co. has a one year low of $182.09 and a one year high of $281.70. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.04 and a current ratio of 1.43. The stock has a market capitalization of $198.06 billion, a P/E ratio of 45.61, a PEG ratio of 4.55 and a beta of 0.83. The stock’s 50-day simple moving average is $270.73 and its 200 day simple moving average is $258.92.

Danaher (NYSE:DHR) last issued its quarterly earnings data on Tuesday, July 23rd. The conglomerate reported $1.72 EPS for the quarter, topping the consensus estimate of $1.57 by $0.15. The firm had revenue of $5.74 billion during the quarter, compared to the consensus estimate of $5.59 billion. Danaher had a return on equity of 11.06% and a net margin of 16.94%. The company’s quarterly revenue was down 2.9% compared to the same quarter last year. During the same period in the prior year, the business posted $2.05 earnings per share. As a group, analysts forecast that Danaher Co. will post 7.59 earnings per share for the current fiscal year.

Danaher Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, October 25th. Investors of record on Friday, September 27th will be issued a $0.27 dividend. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.40%. The ex-dividend date is Friday, September 27th. Danaher’s payout ratio is 18.31%.

Insider Buying and Selling at Danaher

In other Danaher news, CEO Rainer Blair sold 9,007 shares of the stock in a transaction on Wednesday, July 31st. The shares were sold at an average price of $280.00, for a total transaction of $2,521,960.00. Following the transaction, the chief executive officer now directly owns 97,983 shares of the company’s stock, valued at $27,435,240. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In related news, SVP Georgeann Couchara sold 952 shares of Danaher stock in a transaction on Monday, August 26th. The stock was sold at an average price of $268.37, for a total transaction of $255,488.24. Following the completion of the transaction, the senior vice president now directly owns 4,212 shares of the company’s stock, valued at approximately $1,130,374.44. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CEO Rainer Blair sold 9,007 shares of the business’s stock in a transaction that occurred on Wednesday, July 31st. The stock was sold at an average price of $280.00, for a total transaction of $2,521,960.00. Following the sale, the chief executive officer now owns 97,983 shares of the company’s stock, valued at approximately $27,435,240. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 39,659 shares of company stock valued at $11,042,433 in the last quarter. 11.10% of the stock is owned by insiders.

Analyst Ratings Changes

Several research firms have recently issued reports on DHR. Evercore ISI upped their price objective on Danaher from $275.00 to $278.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 1st. Robert W. Baird lifted their price objective on shares of Danaher from $271.00 to $278.00 and gave the stock an “outperform” rating in a research report on Wednesday, July 24th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $300.00 price objective on shares of Danaher in a research report on Friday, September 6th. Barclays increased their price target on shares of Danaher from $270.00 to $285.00 and gave the company an “equal weight” rating in a research note on Wednesday, July 24th. Finally, Bank of America boosted their price target on shares of Danaher from $270.00 to $275.00 and gave the company a “neutral” rating in a report on Wednesday, July 24th. Seven research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. According to data from MarketBeat, Danaher has an average rating of “Moderate Buy” and a consensus target price of $282.12.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.